# Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

> **NCT06455046** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Cervical Cancer Recurrent

## Interventions

- **DRUG:** AK104
- **DRUG:** Recombinant Human Adenovirus 5 Injection

## Key facts

- **NCT ID:** NCT06455046
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-11
- **Primary completion:** 2025-10-10
- **Final completion:** 2025-10-10
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455046, "Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06455046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*